Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Krop ED"'
Autor:
Alečković M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Cristea S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA., Gil Del Alcazar CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Yan P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Ding L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Krop ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Harper NW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Rojas Jimenez E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Lu D; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA., Gulvady AC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Foidart P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Seehawer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA., Diciaccio B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Murphy KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Pyrdol J; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA., Anand J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Garza K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Department of Immunology, Harvard Medical School, Boston, MA, 02115, USA., Tamimi RM; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA., Michor F; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. michor@jimmy.harvard.edu.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, 02138, USA. michor@jimmy.harvard.edu.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA. michor@jimmy.harvard.edu.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. michor@jimmy.harvard.edu.; The Broad Institute of MIT and Harvard, Cambridge, MA, 02138, USA. michor@jimmy.harvard.edu.; The Ludwig Center at Harvard, Boston, MA, 02115, USA. michor@jimmy.harvard.edu., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. kornelia_polyak@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA. kornelia_polyak@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, 02115, USA. kornelia_polyak@dfci.harvard.edu.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; The Broad Institute of MIT and Harvard, Cambridge, MA, 02138, USA. kornelia_polyak@dfci.harvard.edu.; The Ludwig Center at Harvard, Boston, MA, 02115, USA. kornelia_polyak@dfci.harvard.edu.; Harvard Stem Cell Institute, Cambridge, MA, 02138, USA. kornelia_polyak@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2022 Dec 07; Vol. 13 (1), pp. 7558. Date of Electronic Publication: 2022 Dec 07.
Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation.
Autor:
Cai WL; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, United States.; Department of Pathology, Yale University, New Haven, United States., Chen JF; Department of Pathology, Yale University, New Haven, United States., Chen H; Department of Pathology, Yale University, New Haven, United States., Wingrove E; Department of Pathology, Yale University, New Haven, United States., Kurley SJ; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States., Chan LH; Department of Pathology, Yale University, New Haven, United States., Zhang M; Department of Pathology, Yale University, New Haven, United States., Arnal-Estape A; Department of Pathology, Yale University, New Haven, United States.; Yale Cancer Center, Yale School of Medicine, New Haven, United States., Zhao M; Department of Pathology, Yale University, New Haven, United States., Balabaki A; Department of Pathology, Yale University, New Haven, United States., Li W; Yale Cancer Biology Institute, Department of Pharmacology, Yale University, West Haven, United States., Yu X; Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, United States.; Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States., Krop ED; Department of Pathology, Yale University, New Haven, United States.; Department of Biosciences, Rice University,, Houston, United States., Dou Y; Department of Pathology, University of Michigan, Ann Arbor, Ann Arbor, United States.; Department of Medicine, Department of Biochemistry and Molecular Medicine, University of Southern California, Los Angeles, United States., Liu Y; Yale Cancer Center, Yale School of Medicine, New Haven, United States.; Yale Cancer Biology Institute, Department of Pharmacology, Yale University, West Haven, United States., Jin J; Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, United States.; Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States., Westbrook TF; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States., Nguyen DX; Department of Pathology, Yale University, New Haven, United States.; Yale Cancer Center, Yale School of Medicine, New Haven, United States.; Yale Stem Cell Center, Yale School of Medicine, New Haven, United States.; Department of Internal Medicine (Section of Medical Oncology), Yale School of Medicine,, New Haven, United States., Yan Q; Department of Pathology, Yale University, New Haven, United States.; Yale Cancer Center, Yale School of Medicine, New Haven, United States.; Yale Stem Cell Center, Yale School of Medicine, New Haven, United States.; Yale Center for Immuno-Oncology, Yale School of Medicine, New Haven, United States.
Publikováno v:
ELife [Elife] 2022 Aug 31; Vol. 11. Date of Electronic Publication: 2022 Aug 31.
Autor:
Gil Del Alcazar CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Trinh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Alečković M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Rojas Jimenez E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Harper NW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Oliphant MUJ; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Xie S; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Krop ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Lulseged B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Murphy KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Keenan TE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; The Broad Institute, Cambridge, Massachusetts., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; The Broad Institute, Cambridge, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; The Broad Institute, Cambridge, Massachusetts., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Dillon DA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Muthuswamy SK; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.; Department of Medicine, Harvard Medical School, Boston, Massachusetts.; The Broad Institute, Cambridge, Massachusetts.; Harvard Stem Cell Institute, Cambridge, Massachusetts.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2022 Jun 03; Vol. 10 (6), pp. 680-697.